Skip to content
Screener

Acadia Pharmaceuticals ACAD EV / EBITDA

EV / EBITDA at other companies

Biogen logo
BiogenBIIB
17.9×+9.8×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
16.4×-5.2×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
7.9×—

Other financials

Income statement

See full
Revenue$308.0M+16.4%
Gross profit$279.6M+14.7%
Operating income$37.8M+16.9%
Net income$31.5M+18.1%
EPS (diluted)$0.18+12.5%

Balance sheet

See full
Cash & equivalents$385.0M+51.8%
Total debt$73.9M+31.2%
Total equity$1.3B+58.9%
Total assets$1.7B+42.2%

Cash flow

See full
Operating cash flow$100.8M+57.6%
CapEx$5.1M+1,613%
Free cash flow$95.7M+50.3%

Valuation

See full
Market cap$4.9B+23.1%
Enterprise value$4.59B+21.3%
P/E12.9×-5.0×
P/S4.3×+0.4×

Profitability

See full
Gross margin91.1%-0.8pp
Operating margin7.6%-15.7pp
Net margin33.4%+11.6pp
FCF margin18.9%—

Returns & leverage

See full
Return on equity35.7%+2.6pp
Debt / equity0.1×0.0×
Current ratio3.4×+0.5×

Where this comes from

Calculated from Acadia Pharmaceuticals’s reported figures.

enterprise value/ebitda=40.9×

Based on the most recent quarter.

The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333243

FAQ

What is Acadia Pharmaceuticals's EV / EBITDA?
Acadia Pharmaceuticals (ACAD) reported EV / EBITDA of 40.9× in Q2 2026.
How has Acadia Pharmaceuticals's EV / EBITDA changed year-over-year?
Acadia Pharmaceuticals's EV / EBITDA increased by 188.1% year-over-year, from 14.2× to 40.9×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about Acadia Pharmaceuticals's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude